Exactech, Inc. (EXAC) Stock Analysis
DELISTED 2018
What happened to Exactech, Inc. (EXAC) stock?
Exactech, Inc. (EXAC) no longer trades on public markets. It was delisted in February 2018. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Exactech, Inc. (EXAC) trades at $49.25. Exactech, Inc. specializes in the design, development, manufacturing, and marketing of orthopedic implant devices, related surgical instruments, and biologic materials. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for EXAC: EXAC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EXAC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
EXAC: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Exactech, Inc. (EXAC) Healthcare & Pipeline Overview
Exactech, Inc. operates in the orthopedic implant market, providing a range of joint replacement and sports medicine solutions. With a focus on innovation and patient outcomes, the company faces competition from larger players while navigating regulatory landscapes and striving for market share growth.
What Is the Investment Thesis for EXAC?
Investing in Exactech, Inc. requires careful consideration of its position in the competitive orthopedic implant market. The company's focus on innovation and patient outcomes could drive growth, but it faces challenges from larger competitors with greater resources. A key value driver is Exactech's ability to develop and commercialize new products that address unmet clinical needs. The company's gross margin of 68.8% indicates strong pricing power, but its low profit margin of 0.1% raises concerns about operational efficiency. Upcoming catalysts include potential regulatory approvals for new products and expansion into emerging markets. Potential risks include product liability litigation and slower-than-expected adoption of new technologies. Monitoring key metrics such as revenue growth, R&D spending, and market share is crucial for assessing Exactech's long-term prospects.
Based on FMP financials and quantitative analysis
EXAC Key Highlights
Gross margin of 68.8% indicates strong pricing power in the orthopedic implant market.
- Beta of 0.90 suggests lower volatility compared to the overall market.
- Focus on innovation and patient outcomes differentiates Exactech in the competitive orthopedic industry.
- Presence in joint replacement and sports medicine segments provides diversification within the orthopedic market.
- Low profit margin of 0.1% indicates potential areas for operational improvement.
Who Are EXAC's Competitors?
EXAC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| ABT Abbott Laboratories | $114.26 | -0.15% | $198B | 70 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
| EW Edwards Lifesciences Corporation | $92.28 | +1.43% | $53.1B | 93 |
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EXAC's Key Strengths?
Innovative product portfolio.
- Strong relationships with orthopedic surgeons.
- Focus on patient outcomes.
- Established brand reputation.
What Are EXAC's Weaknesses?
Smaller market share compared to larger competitors.
- Low profit margin.
- Limited geographic reach.
- Dependence on key products.
What Could Drive EXAC Stock Higher?
Potential regulatory approvals for new orthopedic implants.
- Expansion of distribution network in emerging markets.
- Development and launch of personalized implants.
What Are the Key Risks for EXAC?
Rich valuation — a P/E of 4279.9 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Product liability claims related to orthopedic implants.
- Intense competition from larger orthopedic companies.
- Regulatory changes affecting the orthopedic device industry.
- Economic downturns impacting healthcare spending.
What Are the Growth Opportunities for EXAC?
- Expansion into emerging markets: Exactech can pursue growth by expanding its presence in emerging markets such as Asia-Pacific and Latin America. These regions offer significant growth potential due to increasing healthcare spending and rising demand for orthopedic procedures. The market size for orthopedic devices in emerging markets is projected to reach $15 billion by 2027. This expansion could involve establishing distribution partnerships, building local manufacturing facilities, and tailoring products to meet the specific needs of these markets.
- Development of personalized implants: Exactech can invest in the development of personalized implants that are tailored to the individual patient's anatomy and biomechanics. Personalized implants can improve surgical outcomes, reduce the risk of complications, and enhance patient satisfaction. The market for personalized implants is estimated to reach $5 billion by 2028. This growth opportunity requires investments in advanced imaging technologies, 3D printing capabilities, and data analytics.
- Adoption of robotic-assisted surgery: Exactech can integrate its implants and instruments with robotic-assisted surgical systems. Robotic-assisted surgery can improve surgical precision, reduce tissue damage, and shorten recovery times. The market for robotic-assisted surgery in orthopedics is projected to reach $3 billion by 2027. This growth opportunity involves partnering with robotic surgery companies and developing specialized instruments and implants for use with these systems.
- Focus on sports medicine: Exactech can expand its presence in the sports medicine market by developing innovative products for the treatment of sports-related injuries. The sports medicine market is driven by increasing participation in sports and recreational activities, as well as advancements in arthroscopic techniques. The global sports medicine market is projected to reach $12 billion by 2028. This growth opportunity requires investments in research and development, clinical trials, and marketing.
- Strategic acquisitions: Exactech can pursue strategic acquisitions of smaller companies with complementary technologies or products. Acquisitions can provide Exactech with access to new markets, technologies, and customers. The orthopedic device industry is characterized by consolidation, with larger companies acquiring smaller players to expand their product portfolios and market share. Exactech can target companies with innovative technologies in areas such as biologics, regenerative medicine, and minimally invasive surgery.
What Are EXAC's Competitive Advantages?
- Proprietary technology in orthopedic implants.
- Strong relationships with orthopedic surgeons.
- Established brand reputation in the orthopedic market.
- Regulatory approvals for orthopedic products.
What Does EXAC Do?
Exactech, Inc. was founded with the mission of improving patient outcomes through innovative orthopedic solutions. The company designs, develops, manufactures, and markets orthopedic implant devices, surgical instruments, and biologic materials. Its primary focus is on joint replacement for knees, hips, and shoulders, as well as sports medicine solutions. Exactech's product portfolio includes a comprehensive range of implants, instruments, and technologies used in orthopedic surgeries. The company has expanded its geographic reach over the years, marketing its products in the United States and internationally. Exactech competes with larger, more established players in the orthopedic industry, emphasizing innovation, product quality, and customer service to differentiate itself. The company's evolution has been marked by continuous product development and strategic partnerships aimed at expanding its market presence and technological capabilities. Exactech strives to provide surgeons with advanced tools and implants to enhance surgical precision and improve patient recovery.
What Products and Services Does EXAC Offer?
- Designs orthopedic implant devices.
- Develops surgical instruments for orthopedic procedures.
- Manufactures orthopedic implants and instruments.
- Markets orthopedic products to hospitals and surgeons.
- Provides biologic materials for orthopedic applications.
- Focuses on joint replacement for knees, hips, and shoulders.
- Offers sports medicine solutions for athletes and active individuals.
How Does EXAC Make Money?
- Develops and manufactures orthopedic implants and instruments.
- Sells products directly to hospitals and surgeons.
- Generates revenue through product sales.
- Invests in research and development to create new products.
What Industry Does EXAC Operate In?
Exactech, Inc. operates within the global orthopedic device market, which is characterized by increasing demand for joint replacement and sports medicine procedures. The market is driven by an aging population, rising obesity rates, and advancements in surgical techniques. Competitive landscape includes large multinational corporations and smaller specialized companies. Exactech focuses on innovation and customer service to differentiate itself. The orthopedic device market is subject to stringent regulatory requirements and product liability risks. Market trends include the adoption of minimally invasive surgical techniques, personalized implants, and robotic-assisted surgery. The global orthopedic device market is projected to reach $60 billion by 2028, growing at a CAGR of 4.5% from 2021.
Who Are EXAC's Key Customers?
- Hospitals
- Orthopedic surgeons
- Ambulatory surgery centers
- Sports medicine clinics
Company Profile
Exactech, Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. EXAC has traded publicly since 1996.
Key Financial Metrics
Return on equity for Exactech, Inc. stands at 0.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.1%, showing how much profit it generates from its asset base. A current ratio of 4.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
EXAC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative product portfolio.
- Strong relationships with orthopedic surgeons.
- Focus on patient outcomes.
- Established brand reputation.
Bear Case
- Smaller market share compared to larger competitors.
- Low profit margin.
- Limited geographic reach.
- Dependence on key products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
EXAC Latest News
No recent news available for EXAC.
Exactech, Inc. Healthcare Stock: Key Questions Answered
What happened to Exactech, Inc. (EXAC) stock?
Exactech, Inc. (EXAC) no longer trades on public markets. It was delisted in February 2018. The figures below are historical and are not a current quote.
Can I still buy EXAC shares?
No. EXAC stopped trading on public markets in February 2018, so the shares are not available through a broker. Anything you see quoted for EXAC elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EXAC stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Exactech, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Exactech, Inc. do?
Exactech, Inc. is a medical device company that designs, develops, manufactures, and markets orthopedic implant devices, related surgical instruments, and biologic materials. The company's primary focus is on joint replacement for knees, hips, and shoulders, as well as sports medicine solutions. Exactech sells its products to hospitals, orthopedic surgeons, and ambulatory surgery centers in the United States and internationally.
What are the main risks for EXAC?
Exactech faces several risks, including product liability litigation related to its orthopedic implants. The company operates in a highly competitive market with larger players, which could limit its ability to gain market share. Regulatory changes in the orthopedic device industry could also impact Exactech's business. Economic downturns could reduce healthcare spending and demand for orthopedic procedures.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for EXAC. Financial data is limited.